Cambrex (NYSE:CBM) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 8th. Analysts expect the company to announce earnings of $0.59 per share for the quarter.
Shares of CBM traded up $0.15 during mid-day trading on Tuesday, hitting $55.32. The company had a trading volume of 6,743 shares, compared to its average volume of 396,839. Cambrex has a 1-year low of $42.55 and a 1-year high of $69.43. The stock has a market capitalization of $1.80 billion, a PE ratio of 17.52, a P/E/G ratio of 1.92 and a beta of 2.42.
CBM has been the topic of several research analyst reports. Jefferies Financial Group initiated coverage on shares of Cambrex in a research report on Tuesday, September 25th. They issued a “buy” rating and a $75.50 target price on the stock. Zacks Investment Research raised shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a research report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $74.25.
In related news, CEO Steven M. Klosk sold 55,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $66.30, for a total value of $3,646,500.00. Following the transaction, the chief executive officer now owns 138,328 shares in the company, valued at $9,171,146.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven M. Klosk sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 23rd. The shares were sold at an average price of $54.76, for a total transaction of $1,095,200.00. Following the completion of the transaction, the chief executive officer now owns 103,328 shares in the company, valued at approximately $5,658,241.28. The disclosure for this sale can be found here. Insiders sold 84,510 shares of company stock worth $5,344,824 over the last three months. Corporate insiders own 2.42% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cambrex (CBM) to Release Quarterly Earnings on Thursday” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/06/cambrex-cbm-to-release-quarterly-earnings-on-thursday.html.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Further Reading: Bear Market
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.